Physician profile
Thomas H Olson
NPI 1134127087
$2,255.64
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $457 · 2021: $800 · 2022: $130 · 2024: $88.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $88.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $88.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.63 | 2019-2022 | |
| Daiichi Sankyo INC. | $243.60 | 2019-2022 | |
| Pfizer INC. | $216.67 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $216.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $194.55 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $152.32 | 2019-2021 | |
| Amgen INC. | $149.82 | 2019-2021 | |
| Allergan, INC. | $99.97 | 2019 | |
| Mylan Specialty L.P. | $95.03 | 2019-2021 | |
| Globus Medical, INC. | $88.24 | 2024 | Proximal Tibia Plate, Evo Antegrade, Distal Radius II |
| Bayer Healthcare Pharmaceuticals INC. | $85.30 | 2021-2022 | |
| Lilly USA, LLC | $82.96 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $74.89 | 2020-2021 | |
| Novo Nordisk INC | $40.25 | 2020-2021 | |
| Astellas Pharma US INC | $34.52 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $27.29 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $19.96 | 2019 | |
| Merck Sharp & Dohme LLC | $15.51 | 2022 | |
| Eisai INC. | $14.88 | 2021 | |
| Abbvie INC. | $14.49 | 2021 | |
| Genentech USA, INC. | $13.50 | 2021 | |
| Adlon Therapeutics L.P. | $11.42 | 2020 | |
| Acadia Pharmaceuticals INC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.